A3160
Acetylsalicylic acid
analytical standard
동의어(들):
2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
Linear Formula:
2-(CH3CO2)C6H4CO2H
CAS 번호:
Molecular Weight:
180.16
UNSPSC Code:
12352106
NACRES:
NA.21
PubChem Substance ID:
EC Number:
200-064-1
Beilstein/REAXYS Number:
779271
MDL number:
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
SMILES string
CC(=O)Oc1ccccc1C(O)=O
grade
analytical standard
form
powder
packaging
vial of 500 mg
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
mp
134-136 °C (lit.)
application(s)
forensics and toxicology
pharmaceutical
veterinary
Quality Level
Gene Information
human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
Biochem/physiol Actions
Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.
Packaging
Supplied in amber screw-cap vials
signalword
Warning
hcodes
저장 등급
11 - Combustible Solids
wgk
WGK 1
flash_point_f
482.0 °F
flash_point_c
250 °C
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.